Literature DB >> 805253

Control of local tumor growth with combined fractionated radiotherapeutic and chemotherapeutic regimens.

L Poulakos, L L Schenken, R F Hagemann, D R Burholt, S Lesher.   

Abstract

A treatment concept for the control of tumor growth utilized weekday radiotherapy and weekend chemotherapy. Mice were given sc injections of P815X2 mastocytoma cells on the lower back (day 0) and separated into the following treatment groups: 5-day/week X-irradiation, adriamycin alone at either 5 mg/kg body wt (days 6 and 13) or 2 mg/kg (days 5, 12, and 19), and combined radiotherapy and chemotherapy. Untreated controls had a mean tumor volume of 2.77 cm-3 and a mean survival time of 24 days. Adriamycin alone at 5 mg/kg resulted in an eventual tumor of 70 percent of the control value at death, whereas at 2mg/kg the tumor volume was 60 percent of control. After radiotherapy only, tumor size was 52 percent of control. Irradiation plus either 5 or 2 mg drug per kg body wt resulted in tumor volumes of 23 and 30 percent, respectively, of control values. Although no treatment regimen prolonged survival, the marked reduction in local tumor growth with combination therapy indicates that it may be a useful concept in future cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 805253     DOI: 10.1093/jnci/54.5.1103

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

1.  Intra-arterial adriamycin chemotherapy for bladder cancer. Semiselective intra-arterial chemotherapy with compression of the femoral arteries at the time of injection.

Authors:  T Uyama; S Moriwaki; M Yonezawa; J Fujita
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  The role of preoperative intra-arterial doxorubicin chemotherapy in combination with low-dose irradiation for bladder cancer.

Authors:  T Uyama; S Moriwaki; A Yokozeki; K Kitada; I Higa; T Shiotsu; J Fujita
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.